New hope for kids with tough tumors: drug combo trial launches

NCT ID NCT04796012

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for children whose solid tumors have returned or not responded to standard therapy. It combines an immunotherapy drug (atezolizumab) with three chemotherapy drugs to see if the mix is safe and can shrink tumors. About 23 children will take part, and the main goals are to check side effects and how well the tumors respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm refractory malignant neoplasm rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHABDOMYOSARCOMA SOLID TUMOR

Contacts and locations

Show contact details

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States
Boston Children's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Cincinnati Children's Hospital
RECRUITING

Cincinnati, Ohio, 45229, United States

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Seattle Children's
RECRUITING

Seattle, Washington, 98105, United States
Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States
The University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.